ARTIKEL: Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes

Center for Diabetes Research’s good friend, Dr. Thomas F. Dejgaard publishes cardiovascular data from the LIRA-1 Trial and shows that liraglutide as an add-on to insulin treatment increased heart rate and did not improve other cardiovascular risk factors in patients with long-standing type 1 diabete​

Redaktør